- Blood from the intestines reaches the liver first, through the portal vein. When the gut wall is more permeable, fragments of bacterial cell wall (LPS) travel with it and can trigger inflammation in the liver.
- In a 2009 preclinical study (Cani et al., Gut), GLP-2 lowered circulating LPS by roughly 50% and restored proteins that seal the gut wall.
- In preclinical studies, BPC-157 was associated with less liver injury, including when the injury was elsewhere in the body (Keles et al., 2025) and after radiation (Xu et al., 2022).
- None of these findings has been tested in a human liver trial. BPC-157 is not approved for any use; the GLP-2 analogue teduglutide (Gattex) is approved only for short bowel syndrome.
- TLR4, NFKB1 and FUT2 variants have been studied for links to inflammation and gut bacteria, but none has been tested against response to either peptide.
Blood leaving the intestines does not go straight into general circulation. It passes through the portal vein to the liver first. That makes the liver the first organ to meet anything absorbed from the gut, including fragments of bacteria when the gut wall is more permeable than usual. Researchers call this relationship the gut-liver axis. This page explains the pathway and what preclinical studies of two peptides, BPC-157 and GLP-2, found about it. It is a summary of research, not a treatment guide.
Reduction in circulating bacterial LPS after GLP-2 in a 2009 preclinical study in Gut (Cani et al.), alongside restored gut-sealing proteins ZO-1 and occludin and fewer immune cells in the liver.
Think of the portal vein as a direct route from the gut to the liver. Nutrients travel it. When the gut wall has gaps, fragments of bacteria travel it too, and the liver's immune cells react to them.
What happens when the gut wall becomes more permeable
The cells lining the intestine are held together by tight-junction proteins, including ZO-1, occludin and claudin-1. When those junctions loosen, gaps open. Bacteria usually stay in the gut, but fragments of their cell walls, called lipopolysaccharides (LPS) or endotoxin, are small enough to pass into the blood.
That LPS reaches the liver through the portal vein. Kupffer cells, the liver's resident immune cells, detect it through a surface receptor called TLR4. TLR4 signals through MyD88 to NF-kB, a master switch for inflammatory genes, leading to release of TNF-alpha, IL-6 and IL-1beta. A 2025 review in Frontiers in Immunology reported higher TLR4 in liver tissue and higher blood LPS in patients with NASH (inflamed fatty liver disease) than in healthy controls.
A finding about liver blood tests
In a 2023 preclinical study in Cell and Molecular Gastroenterology and Hepatology (Trung et al.), GLP-2 reduced liver inflammation scores and scar tissue in a model of bile-driven liver injury, while ALT and AST, the standard liver enzyme tests, did not change significantly. ALT and AST rise mainly when liver cells die and release their contents; they do not directly measure chronic inflammation or scarring. That is a known limit of these tests, and it is why liver assessment is a job for a clinician rather than a single number.
In preclinical studies, it raised KLF4, a protein that dials down oxidative stress and inflammatory genes inside liver cells, and was associated with less liver injury, including when the injury was elsewhere in the body.
In preclinical studies, it tightened gut-sealing proteins and lowered the amount of LPS in the blood. It may also act on the liver's scar-producing cells through a receptor called Nur77.
What the BPC-157 liver studies found
BPC-157 is a 15-amino-acid peptide based on a protein found in human gastric juice. It is best known for preclinical research on soft tissue and gut injury, and its liver research is also preclinical.
A 2025 study in Medicina (Kaunas) (Keles et al.) used a preclinical model in which blood supply to a limb was cut off and restored, which causes inflammatory injury to distant organs. With BPC-157, the liver showed less swelling of small blood channels, fewer invading immune cells, less cell death and restored antioxidant measures.
A 2022 study in Life Sciences (Xu et al.) studied radiation-induced liver injury. BPC-157 raised KLF4 inside liver cells and was associated with less injury and fat accumulation; when KLF4 was knocked down, the protective effect disappeared.
"BPC-157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Knockdown of KLF4 abolished the protective effect, confirming the mechanistic link."
Xu et al., Life Sciences, 2022
| Study | Model | Key liver finding | Proposed mechanism |
|---|---|---|---|
| Keles et al., Medicina, 2025 | Preclinical; limb blood flow cut off and restored | Less liver cell death, swelling and immune-cell influx; restored antioxidant measures | Protection of a distant organ; antioxidant pathway |
| Xu et al., Life Sciences, 2022 | Preclinical; radiation injury to the liver | Less liver injury and fat accumulation | Raised KLF4 inside liver cells |
| Systematic review, American Journal of Gastroenterology, 2025 | 36 preclinical studies, gut and liver | Consistent gut lining repair, restored sealing proteins, fewer inflammatory messengers | The gut's own nerve network; general cell-protective effects |
Consistent results across several groups and injury models are more persuasive than a single study, but they are all preclinical. BPC-157 has no completed human trial for any liver or gut endpoint and is not approved by the FDA for any use. See the BPC-157 reference page for the full evidence summary.
What the GLP-2 studies found
The foundational study (Cani et al., Gut, 2009) used a preclinical model of obesity with chronically raised blood LPS. After GLP-2, blood LPS fell by roughly 50%, the sealing proteins ZO-1 and occludin returned toward normal, immune-cell build-up in the liver fell and oxidative stress markers there improved.
The 2023 Trung et al. study used a preclinical model of persistent bile-driven liver inflammation and scarring. GLP-2 reduced inflammation scores and scar tissue. The proposed mechanism runs through Nur77, a receptor inside the liver's scar-producing cells, suggesting a direct action on the liver as well as at the gut wall.
The GLP-2 analogue teduglutide (Gattex) is FDA-approved for short bowel syndrome. Its approval rests on human trials in that condition, not on liver outcomes. See GLP-2 and gut healing for the human trial record.
Where genetics fits
Inflammatory responses vary between people, and some of the genes on this pathway carry well-studied variants. TLR4 builds the LPS sensor; the Asp299Gly variant (rs4986790) is associated with a weaker response. NFKB1 and RELA build part of the switch that scales inflammatory signalling. FUT2 non-secretors, about 20% of people of European descent (rs601338 AA), have differences in gut bacteria composition.
None of these variants has been tested against response to BPC-157 or GLP-2, and none has been shown to predict liver outcomes from gut permeability in people. A DNA report can show which versions you carry and what the research on them does show; it cannot predict how either peptide would act in you.
The short version: the gut-liver axis is a real pathway with a well-described mechanism. Preclinical studies found that GLP-2 lowered LPS reaching the blood and reduced liver scarring, and that BPC-157 was associated with less liver injury through KLF4. None of this has been tested in a human liver trial. BPC-157 is not approved for any use, and teduglutide is approved only for short bowel syndrome. Liver health questions belong with a clinician.
Frequently asked questions
What is the gut-liver axis?
It is the connection between the intestines and the liver. Blood from the gut reaches the liver first, through the portal vein, so anything absorbed from the gut, including bacterial fragments when the gut wall is more permeable, meets the liver before the rest of the body.
How can gut permeability affect the liver?
When the seals between gut lining cells loosen, fragments of bacterial cell wall (LPS) can pass into the blood and reach the liver through the portal vein. The liver's immune cells detect LPS through TLR4 and release inflammatory messengers. Higher liver TLR4 and blood LPS have been reported in people with NASH.
What did BPC-157 liver studies find?
In preclinical studies, BPC-157 was associated with less liver injury after limb blood flow was cut and restored (Keles et al., 2025) and after radiation (Xu et al., 2022), where the effect depended on raising KLF4. There are no human liver trials, and BPC-157 is not approved by the FDA for any use.
What did GLP-2 studies find?
In a 2009 preclinical study (Cani et al., Gut), GLP-2 lowered blood LPS by roughly 50% and restored gut-sealing proteins. A 2023 preclinical study (Trung et al.) found less liver inflammation and scarring, possibly through the Nur77 receptor. The GLP-2 analogue teduglutide is FDA-approved only for short bowel syndrome.
Why can liver blood tests miss changes in liver inflammation?
ALT and AST rise mainly when liver cells die and release their contents. They do not directly measure chronic inflammation or scarring. In a 2023 preclinical study, GLP-2 reduced liver scarring under the microscope while ALT and AST did not change significantly.
Do genes affect the gut-liver axis?
TLR4, NFKB1, RELA and FUT2 variants have been studied for links to inflammation and gut bacteria. None has been tested against response to BPC-157 or GLP-2.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.